My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 334

    1.

    Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.

    Diabetes Care. 2007 Jun;30(6):1487-93. Epub 2007 Mar 12.PMID: 17353504 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    3.

    The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

    Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

    Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896. PMID: 17404349 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

    Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

    Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M.

    Diabetes Technol Ther. 2007 Aug;9(4):317-26.PMID: 17705687 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.

    Clin Ther. 2008 May;30(5):858-67.PMID: 18555933 [PubMed - indexed for MEDLINE]Related articles

    7.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    8.

    Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.

    Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D.

    Diabetes Technol Ther. 2005 Jun;7(3):467-77.PMID: 15929678 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

    Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

    Diabetes Care. 2005 May;28(5):1083-91.PMID: 15855571 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

    Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.

    Clin Ther. 2007 Jan;29(1):139-53.PMID: 17379054 [PubMed - indexed for MEDLINE]Related articles

    11.

    Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

    Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group.

    Lancet. 2008 Oct 4;372(9645):1240-50. Epub 2008 Sep 7.PMID: 18782641 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group.

    Diabetes Care. 2004 Nov;27(11):2628-35.PMID: 15504997 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

    Diabetes Care. 2005 May;28(5):1092-100.PMID: 15855572 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

    Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

    Diabetes Obes Metab. 2006 Jul;8(4):436-47.PMID: 16776751 [PubMed - indexed for MEDLINE]Related articles

    15.

    Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.

    Mazze R, Strock E, Morgan B, Wesley D, Bergenstal R, Cuddihy R.

    Endocr Pract. 2009 Jul-Aug;15(4):326-34.PMID: 19454385 [PubMed - indexed for MEDLINE]Related articles

    16.

    Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

    Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

    Curr Med Res Opin. 2008 Jan;24(1):275-86.PMID: 18053320 [PubMed - indexed for MEDLINE]Related articles

    17.

    Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

    Curr Med Res Opin. 2009 Jan;25(1):65-75.PMID: 19210140 [PubMed - indexed for MEDLINE]Related articles

    18.

    A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

    Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M.

    Diabetologia. 2007 Feb;50(2):259-67. Epub 2006 Dec 8.PMID: 17160407 [PubMed - indexed for MEDLINE]Related articles

    19.

    Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

    Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD.

    Diabetes Obes Metab. 2006 Jul;8(4):419-28.PMID: 16776749 [PubMed - indexed for MEDLINE]Related articles

    20.

    Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

    Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

    Lancet. 2009 Jul 4;374(9683):39-47. Epub 2009 Jun 8.PMID: 19515413 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity